Introduction {#section5-1756284820911259}
============

It has been widely recognized that preoperative chemoradiotherapy (CRT) combined with total mesorectal excision (TME) is an effective treatment pattern for locally advanced rectal cancer (LARC).^[@bibr1-1756284820911259],[@bibr2-1756284820911259]^ As shown in our previous report, preoperative CRT has a well-established benefit of contributing to tumor response, and, thus, offers an opportunity to patients with low-lying rectal cancer undergoing sphincter-preserving resection.^[@bibr3-1756284820911259],[@bibr4-1756284820911259]^ In addition, 20--30% of patients successfully achieve pathological complete response (pCR) after preoperative CRT, which indicates a favorable prognosis.^[@bibr5-1756284820911259][@bibr6-1756284820911259]--[@bibr7-1756284820911259]^ Nevertheless, pCR does not absolutely represent disease-free survival (DFS) after radical treatment, in that 7.7--11% of patients ultimately develop distant metastasis postoperatively.^[@bibr8-1756284820911259],[@bibr9-1756284820911259]^ Accurate pathological staging is important to determine the recurrence risk and thus provide guidance for postoperative treatment decisions. In this context, there is an urgent need to define pathological parameters related to the survival outcome of patients with pCR.

Some studies have reported that acellular mucin pools are present in 40% of resected rectal specimens after preoperative CRT.^[@bibr10-1756284820911259],[@bibr11-1756284820911259]^ Specifically, for a specimen characterized by both pCR and acellular mucin pools, in order to confirm the true pCR, it is important to identify whether acellular mucin pools are part of the residual tumor or a type of treatment response. However, the prognostic implications of acellular mucin pools for patients undergoing preoperative CRT remain controversial. A previous study reported that acellular mucin pools were indicative of aggressive biological behavior of the malignant tumor, which leads to worse prognosis,^[@bibr11-1756284820911259]^ while other results suggested that acellular mucin pools in rectal cancer after preoperative CRT were not associated with poor prognostic outcomes.^[@bibr12-1756284820911259]^ To date, although several studies have focused specifically on investigating the prognostic significance of acellular mucin pools of pCR specimens, results have failed to reach a unified agreement due to limited sample numbers.^[@bibr13-1756284820911259]^ As it is vital to identify the prognostic implications of acellular mucin pools in LARC patients showing pCR after preoperative CRT, this was the aim of our current study.

Patients and methods {#section6-1756284820911259}
====================

Patient selection {#section7-1756284820911259}
-----------------

The current study collected clinical data from 577 consecutive LARC patients undergoing preoperative chemoradiotherapy and surgery from December 2003 to April 2014 at Sun Yat-sen University Cancer Center, China. The selection criteria for the patients included: (1) pretreatment stage II/III disease (2010 American Joint Committee on Cancer staging system), (2) radical resection for rectal tumor, and (3) postoperative specimen confirmed as pCR. Ultimately, we excluded a total of 460 patients, including 33 patients with distant metastases before CRT, 41 patients receiving palliative tumor resection, 385 patients with non-pCR tumors, and 1 patient having inadequate follow-up data. As a result, 117 patients were selected for this study ([Figure 1](#fig1-1756284820911259){ref-type="fig"}). General patient characteristics, tumor traits, treatment details and follow-up data were recorded from our both electronic medical record system and follow-up tracking system. All procedures were conducted in accordance with the ethical standards of the 2013 World Medical Association Declaration of Helsinki. The requirement for informed consent was waived due to the retrospective nature of the current study; patient data were kept confidential. The current study was approved by the institutional review board of the Independent Ethics Committee at Sun Yat-sen University Cancer Center.

![Flowchart representing the selection of eligible patients for the present study.\
CRT, chemoradiotherapy; pCR, pathological complete response.](10.1177_1756284820911259-fig1){#fig1-1756284820911259}

Treatment {#section8-1756284820911259}
---------

Patients were given preoperative radiation therapy (RT) *via* three-dimensional conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT), with a total dose of 46--50 Gy delivered in daily fractions of 2.0 Gy daily on 5 consecutive days every week. Concurrent chemotherapy included two regimens: (1) the XELOX regimen was performed as 130 mg/m^2^ oxaliplatin administered intravenously on day 1, and 1000 mg/m^2^ capecitabine administered orally twice daily on days 1--14 for a 3-week cycle; (2) the capecitabine alone regimen was performed as 1000 mg/m^2^ capecitabine administered orally twice daily on days 1--14 for a 3-week cycle. If a patient could not tolerate the full dose, or suffered from severe toxic effects, the RT or chemotherapy was stopped. At 6--8 weeks after completion of CRT, the patients were scheduled for TME. XELOX regimen adjuvant chemotherapy was recommended 3--6 weeks after surgery.

Pathological assessment {#section9-1756284820911259}
-----------------------

All resection embedded specimens were assessed by two pathologists. The definition of pCR was the absence of viable tumor cells, with or without fibrotic masses or acellular mucin pools on the proximity to primary tumor and lymph nodes.^[@bibr14-1756284820911259]^ Acellular mucin pools are defined as mucin pools composing over 10% of the entire tumor lesion area as revealed by hematoxylin-eosin (H&E) staining.^[@bibr12-1756284820911259]^ A pathologist, Shixun Lu, reviewed all samples initially diagnosed as 'acellular mucin pools'. Patients were divided into acellular mucin pool and non-acellular mucin pool subgroups based on the presence or absence of acellular mucin pools in rectal primary tumor, as shown in [Figure 2](#fig2-1756284820911259){ref-type="fig"}.

![Representative pathologic micrographs of H&E staining of specimens from patients achieving pCR after preoperative CRT. (a) Presence of acellular mucin pools and (b) absence of acellular mucin pools.\
CRT, chemoradiotherapy; H&E, hematoxylin--eosin; pCR, pathological complete response.](10.1177_1756284820911259-fig2){#fig2-1756284820911259}

Follow up {#section10-1756284820911259}
---------

Patients were recommended to undergo a follow up every 3 months for 2 years after tumor resection, and then every 6 months for 3--5 years. Routine assessment included clinical check-up, carbohydrate antigen (CA19-9) and carcinoembryonic antigen (CEA) testing, abdominopelvic ultrasonography, and chest X-ray. The recommended Chest/abdominal/pelvic computed tomography (CT) and colonoscopy were conducted annually. DFS was defined as the duration from rectal tumor resection to the last follow-up date or tumor recurrence, and overall survival (OS) was recognized as the duration from rectal tumor resection to the last follow-up date or death from any cause. The last follow up was conducted in May 2019.

Statistical analysis {#section11-1756284820911259}
--------------------

Analysis of total data was performed *via* IBM SPSS statistics Version.25 (IBM SPSS INC., Chicago, IL, USA). Chi-squared or Fisher's exact test was applied to compare categorical parameters, which were presented as numbers of cases followed by percentages. Continuous variables were compared using Student's *t* test or the Mann--Whitney *U* test, and were presented as means (standard deviation). Expected 5-year DFS and OS rates were estimated and compared using Kaplan--Meier log-rank test. Potential prognostic factors were selected using univariate Cox models, and statistically significant parameters were further determined by multivariate Cox models. Hazard ratios (HRs) and 95% confidence intervals (CIs) were both generated. *p* values less than 0.05 were considered statistically significant with two-sided statistical tests.

Results {#section12-1756284820911259}
=======

Patient characteristics and treatment {#section13-1756284820911259}
-------------------------------------

Among the 117 patients \[median age 56 years (range 19--85 years)\], 80 (68.3%) were male. After treatment, 27 (23.1%) patients showed acellular mucin pools in rectal specimens, whereas 90 (76.9%) patients did not. Patient characteristics and treatments were compared between the acellular mucin pool group and non-acellular mucin pool group. As a result, age, sex, distance of inferior tumor margin from the anal verge (DAV), pretreatment tumor differentiation, pretreatment CEA, clinical stage, preoperative chemotherapy regimen, total radiation dose, surgical procedure, and patient acceptance of adjuvant chemotherapy were comparable between the two groups ([Table 1](#table1-1756284820911259){ref-type="table"}).

###### 

Comparison of the clinicopathologic characteristics and treatment patterns of patients showing pCR with acellular mucin pools and without acellular mucin pools.

![](10.1177_1756284820911259-table1)

  Variables                                              Total (*n*, %)   Acellular mucin (+) (*n* = 27, %)   Acellular mucin (--) (*n* = 90, %)   *p* value
  ------------------------------------------------------ ---------------- ----------------------------------- ------------------------------------ -----------
  Mean age (±SD, year)                                   53.48 ± 11.8     50.3 ± 13.6                         54.4 ± 11.1                          0.110
  Age (year)                                                                                                                                       
   ⩽60                                                   80 (68.3)        19 (70.4)                           61 (67.8)                            0.799
   \>60                                                  37 (31.7)        8 (29.6)                            29 (32.2)                            
  Sex                                                                                                                                              
   Male                                                  77 (65.8)        18 (66.7)                           59 (65.6)                            0.915
   Female                                                40 (34.2)        9 (33.3)                            31 (34.4)                            
  Baseline DAV                                                                                                                                     
   ⩽5                                                    73 (62.4)        15 (55.6)                           58 (64.4)                            0.403
   \>5                                                   44 (37.6)        12 (44.4)                           32 (35.6)                            
  Pretreatment tumor differentiation                                                                                                               
   Well                                                  30 (25.6)        7 (25.9)                            23 (25.6)                            0.613
   Moderate                                              64 (54.7)        13 (48.1)                           51 (56.7)                            
   Poor                                                  23 (19.7)        7 (25.9)                            16 (17.8)                            
  Clinical stage                                                                                                                                   
   2                                                     42 (35.9)        12 (44.4)                           30 (33.3)                            0.291
   3                                                     75 (64.1)        15 (55.6)                           60 (66.7)                            
  Pretreatment CEA (ng/ml)                                                                                                                         
   ⩽5                                                    80 (68.4)        18 (66.7)                           62 (68.9)                            0.424
   \>5                                                   30 (25.6)        6 (22.2)                            24 (26.7)                            
   Unknown                                               7 (6)            3 (11.1)                            4 (4.4)                              
  Preoperative chemotherapy regimen                                       0.199                                                                    
   XELOX                                                 110 (94)         27 (100)                            83 (92.2)                            
   Capecitabine                                          7 (6)            0                                   7 (7.8)                              
  Radiation dose (Gy)                                                                                                                              
   30--46                                                48 (41)          8 (29.6)                            40 (44.4)                            0.170
   50                                                    69 (59)          19 (70.4)                           50 (55.6)                            
  Interval from the completion of radiation to surgery                                                                                             
   ⩽7                                                    46 (39)          11 (40.7)                           35 (38.9)                            0.863
   \>7                                                   71 (61)          16 (59.3)                           55 (61.1)                            
  Surgical procedure                                                                                                                               
   LAR                                                   77 (65.8)        22 (81.5)                           55 (61.1)                            0.050
   APR                                                   40 (34.2)        5 (18.5)                            35 (38.9)                            
  Adjuvant chemotherapy                                                                                                                            
   Yes                                                   92 (78.6)        23 (85.2)                           69 (76.7)                            0.344
   No                                                    25 (21.4)        4 (14.8)                            21 (23.3)                            

APR, abdominoperineal resection; CEA, carcinoembryonic antigen; DAV, distance of the inferior tumor margin from the anal verge; LAR, low anterior resection; pCR, pathological complete response; SD, standard deviation.

Oncological outcomes {#section14-1756284820911259}
--------------------

During the median follow-up period of 64 months (range 4--125 months), 16 (13.6%) patients developed tumor recurrence, including 1 with locoregional recurrence, 14 with distant metastasis, and 1 with both locoregional recurrence and distant metastasis. As a result, 12 (10.3%) patients died of disease progression. For all patients, the 5-year DFS and OS rates were 90.3% and 86.4%, respectively. The 5-year DFS rate was 96.3% for patients with acellular mucin pools, and 83.7% for patients without acellular mucin pools; these values were comparable (*p* = 0.110) ([Figure 3a](#fig3-1756284820911259){ref-type="fig"}). Similarly, the 5-year OS rate was 100% for patients with acellular mucin pools, and 87.5% for patients without acellular mucin pools; these values were not significantly different (*p* = 0.054) ([Figure 3b](#fig3-1756284820911259){ref-type="fig"}).

![Kaplan--Meier curves comparing 5-year (a) DFS and (b) OS rates based on the presence of acellular mucin pools in patients with pCR after preoperative CRT and radical surgery.\
CRT, chemoradiotherapy; DFS, disease-free survival; OS, overall survival; pCR, pathological complete response.](10.1177_1756284820911259-fig3){#fig3-1756284820911259}

Prognostic analysis of clinical factors {#section15-1756284820911259}
---------------------------------------

In univariate analysis, clinical T4 stage (HR: 3.972, 95% CI: 1.438--10.972, *p* = 0.008), poor tumor differentiation (HR: 3.002, 95% CI: 1.089--8.273, *p* = 0.034), and abdominoperineal resection (HR: 2.844, 95% CI: 1.058--7.644, *p* = 0.038) were associated with shorter DFS. In multivariate analysis, clinical T4 stage (HR: 4.251, 95% CI: 1.494--12.097, *p* = 0.007) and abdominoperineal resection (HR: 4.263, 95% CI: 1.480--12.276, *p* = 0.007) were independent prognostic factors for DFS ([Table 2](#table2-1756284820911259){ref-type="table"}). For OS, univariate analysis revealed that clinical T4 stage (HR: 4.706, 95% CI: 1.413--15.675, *p* = 0.012), poor tumor differentiation (HR: 7.034, 95% CI: 2.229--22.196, *p* = 0.001), and abdominoperineal resection (HR: 6.610, 95% CI: 1.788--24.433, *p* = 0.005) were associated with shorter OS, while a radiotherapy dosage of 50 Gy (HR: 0.253, 95% CI: 0.067--0.946, *p* = 0.041) and preoperative chemotherapy with the XELOX regimen (HR: 0.208, 95% CI: 0.054--0.808, *p* = 0.023) were associated with prolonged OS. In multivariate analysis, clinical T4 stage (HR: 5.460, 95% CI: 1.580--18.865, *p* = 0.007), poor tumor differentiation (HR: 6.687, 95% CI: 1.851--24.158, *p* = 0.004), and abdominoperineal resection (HR: 10.886, 95% CI: 2.568--46.138, *p* = 0.001) were negative prognostic factors for OS ([Table 3](#table3-1756284820911259){ref-type="table"}).

###### 

Univariate and multivariate analyses of prognostic factors for the DSF of patients with pCR after preoperative chemotherapy.

![](10.1177_1756284820911259-table2)

  Variable                                                  Univariate              Multivariate                           
  --------------------------------------------------------- ----------------------- -------------- ----------------------- -------
  Age \>60 years                                            0.222 (0.029--1.684)    0.145                                  
  Gender (female)                                           2.651 (0.987--7.121)    0.053                                  
  Clinical T stage 4                                        3.972 (1.438--10.972)   0.008          4.251 (1.494--12.097)   0.007
  Clinical N stage 1/2                                      0.969 (0.351--2.673)    0.951                                  
  Baseline DAV ⩽ 5 cm                                       1.820 (0.586--5.653)    0.301                                  
  Poor tumor differentiation                                3.002 (1.089--8.273)    0.034          2.848 (0.980--8.271)    0.054
  Baseline CEA \> 5 ng/ml                                   1.796 (0.649--4.972)    0.259                                  
  Radiotherapy dose (50 Gy)                                 0.751 (0.279--2.021)    0.571                                  
  Preoperative chemotherapy (XELOX regimen)                 0.473 (0.106--2.118)    0.328                                  
  Interval from the end of radiation to surgery \>7 weeks   0.681 (0.255--1.822)    0.445                                  
  Abdominoperineal resection                                2.844 (1.058--7.644)    0.038          4.263 (1.480--12.276)   0.007
  Acceptance of adjuvant chemotherapy                       0.568 (0.197--1.635)    0.294                                  
  Acellular mucin pool (+)                                  0.222 (0.029--1.684)    0.145                                  

CEA, carcinoembryonic antigen; CI, confidence interval; DAV, distance of the inferior tumor margin from the anal verge; DSF, disease-free survival; HR, hazard ratio; pCR, pathological complete response.

###### 

Univariate and multivariate analyses of prognostic factors for the OS of patients with pCR after preoperative chemotherapy.

![](10.1177_1756284820911259-table3)

  Variable                                                  Univariate              Multivariate                            
  --------------------------------------------------------- ----------------------- -------------- ------------------------ -------
  Age \>60 years                                            1.082 (0.326--3.595)    0.898                                   
  Gender (female)                                           1.423 (0.452--4.484)    0.547                                   
  Clinical T stage 4                                        4.706 (1.413--15.675)   0.012          5.460 (1.580--18.865)    0.007
  Clinical N stage 1/2                                      1.183 (0.355--3.938)    0.784                                   
  Baseline DAV ⩽ 5 cm                                       6.569 (0.846--51.006)   0.072                                   
  Poor tumor differentiation                                7.034 (2.229--22.196)   0.001          6.687 (1.851--24.158)    0.004
  Baseline CEA \>5 ng/ml                                    2.110 (0.667--6.672)    0.204                                   
  Radiotherapy dose (50 Gy)                                 0.253 (0.067--0.946)    0.041          0.493 (0.111--2.192)     0.353
  Preoperative chemotherapy (XELOX regimen)                 0.208 (0.054--0.808)    0.023          0.546 (0.124--2.409)     0.546
  Interval from the end of radiation to surgery \>7 weeks   0.513 (0.161--1.628)    0.257                                   
  Abdominoperineal resection                                6.610 (1.788--24.433)   0.005          10.886 (2.568--46.138)   0.001
  Acceptance of adjuvant chemotherapy                       0.496 (0.149--1.647)    0.252                                   
  Acellular mucin pool (+)                                  0.033 (0.000--9.620)    0.238                                   

CEA, carcinoembryonic antigen; CI, confidence interval; DAV, distance of the inferior tumor margin from the anal verge; HR, hazard ratio; pCR, pathological complete response.

Discussion {#section16-1756284820911259}
==========

Our current study reported a 27% prevalence of acellular mucin pools present in rectal specimens from patients with pCR following preoperative CRT. The presence of acellular mucin pools did not show an association of any patient characteristics, tumor trait, or treatment pattern. In addition, our results revealed comparable long-term survival among patients with pCR with and without acellular mucin pools. Thus, we suggest that acellular mucin pools after preoperative CRT do not have a significant prognostic impact on LARC patients who achieve pCR.

To date, five studies have revealed the prevalence rates of acellular mucin pools in rectal specimens from patients showing pCR ([Table 4](#table4-1756284820911259){ref-type="table"}).^[@bibr9-1756284820911259],[@bibr13-1756284820911259][@bibr14-1756284820911259][@bibr15-1756284820911259][@bibr16-1756284820911259]--[@bibr17-1756284820911259]^ Among these studies, the proportion of acellular mucin pools on rectal tumor specimens was identified in between 16.1% and 34.2% of cases. In the current study, the prevalence of acellular mucin pools was 27%, and thus falls within this range of 16.1--34.2%. Therefore, the existence of acellular mucin pools in rectal specimens from patients achieving pCR is not a rare phenomenon, which warrants careful pathological assessment. A study by Lim and colleagues revealed that the presence of acellular mucin pools was related to poor tumor differentiation, male gender, and a short duration between CRT and tumor resection.^[@bibr15-1756284820911259]^ In contrast, other studies, including ours, observed that the presence of acellular mucin pools was not related to any specific patient characteristics, tumor trait, or treatment.^[@bibr16-1756284820911259],[@bibr18-1756284820911259]^ The association of various clinical factors with the presence of acellular mucin pools after treatment with preoperative CRT needs further validation in future studies.

###### 

Studies of patients with locally advanced rectal cancer showing pCR after preoperative chemoradiotherapy followed by total mesorectal excision.

![](10.1177_1756284820911259-table4)

  Study                                       Number of patients   Patients with acellular mucin (*n*, %)   Median/mean follow up (months)   Estimated survival period   DFS rate               *p* value   OS rate                *p* value
  ------------------------------------------- -------------------- ---------------------------------------- -------------------------------- --------------------------- ---------------------- ----------- ---------------------- -----------
  Lim^[@bibr15-1756284820911259]^             217                  35 (16.1)                                41                               3 years                     97% *versus* 93%       0.131       96.8% *versus* 95.9%   0.314
  Bhatti^[@bibr13-1756284820911259]^          35                   12 (34.2)                                36                               5 years                     73% *versus* 89%       0.100       75% *versus* 87%       0.400
  Campos-Lobato^[@bibr16-1756284820911259]^   58                   11 (19)                                  43                               3 years                     79% *versus* 95%       0.140       83% *versus* 95%       0.150
  Smith^[@bibr17-1756284820911259]^           100                  27 (27)                                  87                               7 years                     81% *versus* 87%       0.764       85% *versus* 92%       0.954
  Sun^[@bibr9-1756284820911259]^              118                  32 (27.1)                                57                               5 years                     67.4% *versus* 96.5%   0.003       89.8% *versus* 96.5%   0.210
  Present study                               117                  27 (23.1)                                64                               5 years                     100% *versus* 87.5%    0.054       96.3% *versus* 83.7%   0.110

DFS, disease-free survival; OS, overall survival; pCR, pathological complete response.

Reviewing the available series of studies, the prognostic implications of acellular mucin pools in resected rectal specimens from patients showing pCR are still not well understood and remain under debate. Recently, a study by Sun and colleagues demonstrated that pCR patients with acellular mucin pools have a poorer DFS rate (67.4% *versus* 96.5%, *p* = 0.003) compared with those without acellular mucin pools, which revealed acellular mucin pools as a possible indicator of aggressive biological behavior of the tumor.^[@bibr9-1756284820911259]^ Similarly, despite a lack of statistical evidence, Campos-Lobato and colleagues and Bhatti AB and colleagues both observed a tendency for pCR patients with acellular mucin pools to present increased distant metastasis and reduced DFS and OS rates.^[@bibr16-1756284820911259],[@bibr18-1756284820911259]^ Inconsistent with the results of these latter two studies, Lim and colleagues demonstrated that the presence of acellular mucin pools had no significant association with poor outcome in DFS (97.0% *versus* 93.0%, *p* = 0.131) and OS (96.8% *versus* 95.9%, *p* = 0.314) rates, which were rather similar between the patients with and without acellular mucin pools, respectively.^[@bibr15-1756284820911259]^ In addition, a study by Smith and colleagues reported similar 7-year DFS (81% *versus* 87%, *p* = 0.764) and OS (85% *versus* 92%, *p* = 0.954) rates in patients with and without acellular mucin pools, respectively.^[@bibr17-1756284820911259]^ In our study, we even found a trend that patients with acellular mucin pools have a slightly superior 5-year DFS (96.3% *versus* 83.7%, *p* = 0.110) and OS (100% *versus* 87.5%, *p* = 0.054) rates than those without acellular mucin pools.

The inconsistency in these results can be attributed to the following: determination of the prognostic implication of acellular mucin pools is constrained by small sample size.^[@bibr16-1756284820911259],[@bibr18-1756284820911259]^ As shown in [Table 4](#table4-1756284820911259){ref-type="table"}, the number of patients showing pCR with acellular mucin pools was very small, ranging from 11 to 35 patients in each study, which impaired the statistical power to identify the survival difference between the two groups. Another important reason concerns the accuracy of the pathological diagnosis of acellular mucin pools. Distinct acellular mucin pools were well defined as constituting an area over 10% of the entire tumor lesion area. However, the assessment of acellular mucin pools involves a combination of the following factors: the amount of acellular mucin pools in the entire tumor lesion, tumor cell cellularity in mucin pools, and the location of acellular mucin pools in the bowel wall.^[@bibr12-1756284820911259]^ However, most of the studies cited did not note details of the assessment of acellular mucin pools in rectal tumor specimens; subtle differences in the pathological assessment of acellular mucin pools inevitably exist among studies, which might lead to different results. In addition, the distinct follow-up duration was not a negligible factor. In the studies by Lim and colleagues, Campos-Lobato and colleagues, and Bhatti AB and colleagues, the median follow-up duration was less than 5 years.^[@bibr15-1756284820911259],[@bibr16-1756284820911259],[@bibr18-1756284820911259]^ The relatively short follow up may not accurately determine the effect of acellular mucin pools on long-term survival.

To date, the necessity for adjuvant chemotherapy for LARC patients who achieve pCR after preoperative CRT and radical surgery is still unclear.^[@bibr19-1756284820911259][@bibr20-1756284820911259]--[@bibr21-1756284820911259]^ In the current study, 85.2% (23/27) of patients with acellular mucin pools received adjuvant chemotherapy. On account of the small sample size of the patients showing acellular mucin pools, we could not define the efficiency of adjuvant chemotherapy for acellular mucin pools. The therapeutic role of adjuvant chemotherapy in patients showing pCR and acellular mucin pools urgently needs to be demonstrated. Accordingly, postoperative management decisions should be judicious of particular patient characteristics and tumor traits. Our previous findings showed that oxaliplatin-containing adjuvant chemotherapy may offer survival benefits to patients showing pCR after preoperative CRT and radical surgery, especially to those aged \<60 years.^[@bibr22-1756284820911259]^ Additionally, the current study found that the clinical T4 stage, poor tumor differentiation, and abdominoperineal resection were negative prognostic factors for patients achieving pCR after preoperative CRT. Thus, we considered that adjuvant chemotherapy should also be recommend to patients with these risk factors.

Several limitations of our study need to be pointed out. Firstly, the current study was conducted using a retrospective method with a limited volume size of patients from a single center. Patient selection and treatment bias were unavoidable. Secondly, the lack of validation for the results from centers was another limitation of the study. Thirdly, pretreatment molecular features of tumors that might be related to the occurrence of acellular mucin pools, such as expression of the mismatch repair protein (MMR) and the mutation of KRAS, BRAF, and PIK3CA oncogenes, were also not investigated. In the cohort in the study by Sun and colleagues, positive mucin 1 staining was significantly associated with the presence of acellular mucin pools, and the expression level was higher in patients with acellular mucin pools than in patients without acellular mucin pools.^[@bibr9-1756284820911259]^ Fourthly, we failed to record the number and location of acellular mucin pools in the bowel wall. The prognostic implication of different patterns of mucin pools warrants further investigation.

Conclusion {#section17-1756284820911259}
==========

In summary, our current study provided more concrete evidence that acellular mucin pools are not associated tumor cells, and thus have no significant adverse impact on the long-term survival of patients achieving pCR after preoperative CRT. We look forward to studies with large sample numbers that will further investigate this topic and provide a better understanding of the prognostic significance of acellular mucin pools.
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